Getinge has secured approval from the US Food and Drug Administration (FDA) for its new mechanical ventilator, Servo-air Lite.
The company has developed a new turbine-driven ventilator for non-invasive ventilation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new ventilator provides ICU-level ventilation just like all other Servo ventilators and is aimed at spontaneously breathing patients who require enhanced breathing support.
It has an advanced turbine and a durable battery backup, it can function independently without relying on wall gas and is also suitable for intrahospital transportation.
Furthermore, the ventilator features embedded workflows, high-flow therapy support and the option to monitor CO₂, as well as tools to support escalating the therapy if necessary.
Getinge acute care therapies president Elin Frostehav said: “We are happy to broaden our ventilator product offering for the US market.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This significantly increases our addressable ventilation market in the US, by now being able to target the non-invasive hospital segment with our ventilation offering.”
Servo-air Lite is expected to be available for customers in the US from September this year.
The company also offers Servo-air wall-gas-independent mechanical ventilators for adult and paediatric patients.
The company’s other products include the Servo-u mechanical ventilator, the Servo-neonatal ventilator, the Servo-air NIV mechanical ventilator and the Servo-u MR conditional ventilator.
With more than 10,000 employees across the world, Getinge provides products and solutions to hospitals and life science institutions.
The company markets its products in more than 135 countries.
